期刊文献+

类风湿性关节炎伴间质性肺病中肿瘤标志物对肺功能的影响分析 被引量:5

The Influence of Tumor Markers in Rheumatoid Arthritis with Interstitial Lung Disease on Lung Function
原文传递
导出
摘要 目的:探究类风湿性关节炎伴间质性肺病中肿瘤标志物对肺功能的影响。方法:选取2011年3月至2013年3月我院收治的类风湿性关节炎患者88例,根据其是否伴有ILD,分为RA组53例和RA-ILD组35例。检测两组肺功能指标用力肺活量(FVC)、1s用力呼气容积(FEV1)、最大通气量百分比(MVV)、一氧化碳弥散量(DLCO),肿瘤标志物癌胚抗原CEA、癌抗原125(CA125)、癌抗原199(CA199)及抗环胍氨酸肽抗体(抗CCP抗体)的值,并利用统计学方法分析肿瘤标记物与肺功能指标、抗CCP抗体的相关性。结果:RA-ILD组FVC、FEV1、MVV、DLCO均比RA组低,CEA、CA125、CA199均比RA组高,结果比较差异显著具有统计学意义(P<0.05)。但两组抗CCP抗体含量相比却无明显差异,不具有统计学意义(P>0.05)。相关性分析显示,CEA与FVC、FEV1、MVV、DLCO呈负相关(P<0.05),而CA125、CA199却与肺功能指标无相关性,CEA、CA125、CA199与抗CCP抗体均无相关性(P>0.05)。结论:RA-ILD的肺功能指标均有明显下降,而肿瘤标志物表达水平却明显增高,CEA对肺功能损害影响较大,却与关节损害的关系不大,这为临床对类风湿性关节炎伴间质性肺病早诊断、早治疗提供了依据。 Objective: To observe the influence of tumor markers in rheumatoid arthritis with interstitial lung disease on lung func- tion. Methods: We select 88 rheumatoid arthritis patients accepted by our hospital from March 2011 to March 2013, in accordance with its associated ILD or not, were divided into RA group (53 cases) and RA-ILD group (35 cases), we detectedlungfunctionoftwogroups, in- cluding forced vital capacity (FVC), 1 s forced expiratory volume (FEV1), percentage of maximum voluntary ventilation (MVV), carbon monoxide diffusing capacity (DLCO). And we detectedtumor markers, including carcinoembryonic antigen (CEA), cancer antigen 125 (CA125), cancer antigen 199 (CA199) and anti-cyclic citrulline peptide antibodies (anti-CCP) values, and then the statistical methods were used to analyse the correlation of tumor markers with lung function and anti-CCP antibody. Results: The FVC, FEV1, MVV and D1- CO of RA-ILD group were less than that of the RA grOup and the CEA, CA125, CA199 were higher, the results were statistically signifi- cant (P〈0.05). theanti-CCPantibodylevels ofthetwogroups were comparivel levels with no significant difference (P〉0.05). Correlation analysis showed that CEA and FVC, FEV1, MVV, DLCO was negatively correlated (P 〈0.05), CA125, CA199 with lung function and CEA, CA125, CA199 with anti-CCP antibodies had no correlation (P〉 0.05). Conclusion: The lung function indexes of RA-ILD are sig- nificantly decreased and tumor marker expression levels are significantly higher, CEA had greater impact on lung function damage, but it has little to do with the joint damage. It provides the basis for the clinical to give early diagnosis and early treatment to rheumatoid arthri- tis with interstitial lung dis- ease.
出处 《现代生物医学进展》 CAS 2013年第25期4885-4887,4935,共4页 Progress in Modern Biomedicine
基金 国家临床重点专科建设项目经费资助
关键词 类风湿性关节炎 间质性肺病 肿瘤标志物 Rheumatoid arthritis Interstitial lung disease Tumor marker
  • 相关文献

参考文献20

  • 1Koduri G, Norton S, Young A, et al. Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an inception cohort[J]. Rheumatology(Oxford), 2010, 49(8): 1483-1489. 被引量:1
  • 2Brown KK. Rheumatoid lung disease[J]. Proc Am Thorac Soc, 2007, 4 (5): 443-448. 被引量:1
  • 3Guerra M, Miranda JA, Leal F, et al. Interstitial lung disease'. Diagnos- tic accuracy and safety of surgical lung biopsy [J]. Rev Port Pneumol, 2009, 15(3): 433-442. 被引量:1
  • 4Nakayama S, Yokote T, Kobayashi K, et al. Megaloblastic anemia as- sociated with salazosulf apyridine treatment for rheumatoid arthritis [J]. Rinsho Ketsueki, 2008, 49( 12): 1609-1613. 被引量:1
  • 5Neurohr C, Behr J. Diagnosis and therapy of interstitial lung diseases [J]. Dtsch Med Wochenschr, 2009, 134(11):524-529. 被引量:1
  • 6Amett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis[J]. Arthritis Rheum, 1988,31(3): 315-324. 被引量:1
  • 7Dawson JK, Fewins HE, Desmond J, et al. Predictiors of progression of HRCT diagnosed fibrosing alveolitis in patients with rheumatoid arthritis[J]. Ann Rheum Dis, 2002,61:517-522. 被引量:1
  • 8Riley DJ, Costanzo EJ. Surgical biopsy: its appropriateness indiagnos- ing interstitial lung disease [J]. Curt Opin Pulm Med, 2006, 12(5): 331-336. 被引量:1
  • 9Zielonka TM. Angiogenesis in interstitial lung diseases[J]. Pneumonol Alergol Pol, 2009, 77(1): 52-60. 被引量:1
  • 10Raghu G, Brown KK, Bradford WZ, et al. A placebo controlled triai of interferon gamma- lb in patients with ideopathic pulmonary fibro- sis[J]. N Eng J Med, 2004, 350(2): 125-133. 被引量:1

二级参考文献20

  • 1时广利,胡秀玲,岳思东,宋长兴.血清肿瘤标志物在肺癌辅助诊断中的应用[J].中华肿瘤杂志,2005,27(5):299-301. 被引量:82
  • 2Angelopoulou K, Yu H, Bharaj B, et al. P53 gene mutation, tumor p53 protein overexpression, and serum p53 autoantibody generation in pa- tients with breast cancer[J]. Clin Biochem,2000,33(1):53-62. 被引量:1
  • 3Boyle P, Chapman CJ, Holdenrieder S, et,al.Clinical validation of an autoantibody test for lung cancer. 2011 Feb;22(2):383-389. 被引量:1
  • 4Kulpa J, Wo jcik E, Reinfuss M, et al. CarcinoembryonicAntigen, Squamous cell Carcinoma Antigen, CYFRA2 1-1, and Neuron specific Enolase in Squamous Cell Lung Cancer Patients [J]. Clinical Chem- istry, 2002, 48(11):1931-1937. 被引量:1
  • 5Mitsudomi T, Suzuki S, Yatabe Y, et al. Clinical implications of p53 autoantibodies in the sera of patients with non small-cell lung cancer.J Natl Cancer Inst, 1998,90(20): 1563 - 1568. 被引量:1
  • 6Poleri C, Morero JL, Nieva B, et al. Risk of recurrence in patients with surgically resected stage I non-small cell lung carcinoma: histopatho- logic and immunohistochemical analysis [J]. Chest, 2003 Jun;123(6):1858-1867. 被引量:1
  • 7Niklinska W, Burzykowski T, Laudanski J, et al. Strong association between P53 protein accumulation, serum antibodies and gene muta- tion in non-small cell lung cancer [J]. Folia Histochem Cytobiol, 2001,39(2): 51-56. 被引量:1
  • 8Cedr6 s S, Nufiez I, Longo M, Martinez P, et al. MDA and SOD con- tent in blood serum Serumtumor markers CEA, CYFRA21-1, and CA-125 are associated with worse prognosis in advanced non-small-cell lung cancer (NSCLC)[J]. Clin Lung Cancer, 2011 May, 12(3):172-179. 被引量:1
  • 9Zabarovsky R, Leman MI, Minna JD, et al. Tumor suppressor genes onchromosome 3p involved in the pathogenesis of lung and other cancer[J]. Oncogene, 2002, 21 (45):6915-6935. 被引量:1
  • 10Robles AI, Link SP, Harris CC, et al. The P53 network in lung caminogenesis[J]. Oncogene, 2002, 2(1):6898-6907. 被引量:1

共引文献9

同被引文献53

  • 1胡盈莹,胡望平,黄兢姚,冯福英,王海林,汪升,章宏斌,周长邵.癌抗原在胸腹腔积液及相关疾病诊断与治疗中的应用[J].实用诊断与治疗杂志,2007,21(3):168-170. 被引量:7
  • 2Klareskog L, Catrina AI, Paget S. Rheumatoid arthritis [J]. Lancet, 2009, 373:659-672. 被引量:1
  • 3Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League against Rheumatism collaborative initiative [ J]. Ann Rheum Dis, 2010, 69 : 1580-1588. 被引量:1
  • 4Szekaneez E, Szucs G, Szekaneez Z, et al. Tumor- associated antigens in systemic sclerosis and lupus erythematosus: association with organ manifestation, immunolaboratory markers and disease activity indices [ J]. J Autoimmun, 2008, 12:372-376. 被引量:1
  • 5Safadi R, Ligumsky M, Goldin E, et al. Increased serum CA 19-9 antibodies in Sjtigren' s syndrome [ J ]. Postgrad Med ], 1998, 74:543-544. 被引量:1
  • 6Basaran A, Zafer Tuneer S. Aseites is the primary cause of cancer antigen-125 ( CA-125 ) elevation in systemic lupus erythematosus (SLE) patients with nephrotie syndrome [ J ]. Med Hypotheses, 2007, 68 : 197-201. 被引量:1
  • 7Yang Z, Liang Y, Li C, et al. Serum CA125 elevationis independently associated with serositis in SLE patients [ J]. Clin Exp Rheumatol, 2012, 30:93-98. 被引量:1
  • 8Celeste S, Santaniello A, Caronni M, et al. Carbohydrate antigen 15.3 as a serum biomarker of interstitial lung disease in systemic sclerosis patients [J]. Eur J Intern Med, 2013, 10:671-676. 被引量:1
  • 9Szekanecz E, S6ndor Z, Antal-Szalmas P, et al. Increased Production of the Soluble Tumor-Associated Antigens CA19-9, CA125, and CA15-3 in Rheumatoid Arthritis I J]. Ann NY Acad Sci, 2007, 1108: 359-371. 被引量:1
  • 10Bergamaschi S, Morato E, Bazzo M, et al. Tumor markers are elevated in patients with rheumatoid arthritis and do not indicate presence of cancer [J]. Int Rheum Dis, 2012, 15:179-182. 被引量:1

引证文献5

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部